Effect of Conbercept on Corneal Neovascularization in a Rabbit Model

High-efficiency antioxidant ROS-responsive thermosensitive hydrogel encapsulated Fenofibrate for the treatment of corneal neovascularization

Corneal neovascularization (CNV) has become one of the common blinding ocular diseases recognized worldwide, affecting millions of people every year. Numerous studies have shown that oxidative stress and inflammation are important factors for the occurrence and development of CNV. In the present study, we established an antioxidant and reactive oxygen species (ROS) responsive thermosensitive hydrogel for long-acting drug delivery, combining with the loaded anti-angiogenic drug to the therapy for CNV. Se-PEG-PPG (SePEP) could in-situ gelling on the ocular surface temperature and cover the ocular surface. The hydrophobic interaction between the selenium ether segment and ocular mucin will further increase its adhesion on the ocular surface, which is conducive to drug Fenofibrate (Feno) retention and sustained release on the ocular surface. SePEP also played a role in reducing intracellular oxidative stress and oxidative responsive sustained release drug due to its selenium ether groups that scavenge ROS. Finally, the combined anti-oxidation, anti-inflammation, and anti-angiogenesis therapeutic effect of Feno@Se-PEG-PPG (SePEP-Feno) eye drops were demonstrated in a corneal neovascularization animal model. In conclusion, the multifunctional delivery system provided a promising method for the treatment of CNV and various ROS-related ocular diseases.

Management of corneal neovascularization: Current and emerging therapeutic approaches

Corneal neovascularization (CoNV) is a sight-threatening condition affecting an estimated 1.4 million people per year, and the incidence is expected to rise. It is a complication of corneal pathological diseases such as infective keratitis, chemical burn, corneal limbal stem cell deficiency, mechanical trauma, and immunological rejection after keratoplasties. CoNV occurs due to a disequilibrium in proangiogenic and antiangiogenic mediators, involving a complex system of molecular interactions. Treatment of CoNV is challenging, and no therapy thus far has been curative. Anti-inflammatory agents such as corticosteroids are the mainstay of treatment due to their accessibility and well-studied safety profile. However, they have limited effectiveness and are unable to regress more mature neovascularization. With the advent of advanced imaging modalities and an expanding understanding of its pathogenesis, contemporary treatments targeting a wide array of molecular mechanisms and surgical options are gaining traction. This review aims to summarize evidence regarding conventional and emerging therapeutic options for CoNV.